Real-life effectiveness of afatinib versus gefitinib in patients with non-small-cell lung cancer: a Czech multicentre study
M Svaton, M Bratová, O Fischer, J Krejci… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …
small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) …
[HTML][HTML] Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib
Y Kim, SH Lee, JS Ahn, MJ Ahn… - Cancer Research and …, 2019 - synapse.koreamed.org
Purpose We tried to evaluate whether there are any specific features in treatment outcomes
of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small …
of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small …
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib
M Schuler, JR Fischer, C Grohé, S Gütz… - The …, 2014 - academic.oup.com
Abstract Background. Afatinib, an irreversible ErbB family blocker, demonstrated superiority
to chemotherapy as first-line treatment in patients with EGFR-mutated non-small cell lung …
to chemotherapy as first-line treatment in patients with EGFR-mutated non-small cell lung …
Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-mutated population with advanced non-small-cell lung cancer.
C Chouaid, L Luciani, K Le Lay, G De Pouvourville - 2017 - ascopubs.org
e20548 Background: The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib were compared in the multicenter, international …
tyrosine kinase inhibitor gefitinib were compared in the multicenter, international …
A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer …
T Ninomiya, N Nogami, T Kozuki, D Harada, T Kubo… - Lung Cancer, 2018 - Elsevier
Objective In advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung
cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase …
cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase …
Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data
A Passaro, A Pochesci, G Spitaleri… - Expert Review of …, 2016 - Taylor & Francis
Introduction: Epidermal growth factor receptor (EGFR) mutations are detected in about 10–
15% of Caucasian and 30–40% of Asian patients with advanced or metastatic non-small-cell …
15% of Caucasian and 30–40% of Asian patients with advanced or metastatic non-small-cell …
[HTML][HTML] Afatinib and gefitinib: a direct comparison
C Gridelli, T Losanno - Translational Cancer Research, 2016 - tcr.amegroups.org
Afatinib and gefitinib: a direct comparison - Gridelli - Translational Cancer Research Have a
website account?Log In orRegister for exclusive website content. Subscribe Advanced …
website account?Log In orRegister for exclusive website content. Subscribe Advanced …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
Efficacy and safety of afatinib in advanced non-small cell lung cancer with EGFR mutations: A real-world study based meta-analysis.
L Zhang - 2021 - ascopubs.org
e21134 Background: This study aimed to explore the efficacy and safety of Afatinib in
advanced EGFR mutation NSCLC patients based on real-world evidence. We also explore …
advanced EGFR mutation NSCLC patients based on real-world evidence. We also explore …